Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives $41.56 Consensus PT from Analysts

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has earned a consensus rating of “Moderate Buy” from the ten ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $41.7778.

Several research analysts have issued reports on TEVA shares. Scotiabank raised their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Piper Sandler reissued an “overweight” rating and set a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Bank of America boosted their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Finally, UBS Group upped their price objective on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th.

Insiders Place Their Bets

In related news, EVP Richard Daniell sold 30,000 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total value of $1,062,000.00. Following the transaction, the executive vice president directly owned 55,755 shares in the company, valued at $1,973,727. This trade represents a 34.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the transaction, the executive vice president directly owned 63,647 shares in the company, valued at $2,247,375.57. This represents a 25.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 1,127,018 shares of company stock valued at $37,298,712. 0.54% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Norges Bank purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $1,098,060,000. WCM Investment Management LLC boosted its stake in shares of Teva Pharmaceutical Industries by 191.4% in the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after buying an additional 26,813,522 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 19.2% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after buying an additional 7,255,083 shares in the last quarter. Wellington Management Group LLP grew its holdings in Teva Pharmaceutical Industries by 39,228.4% during the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after acquiring an additional 6,878,304 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd grew its holdings in Teva Pharmaceutical Industries by 18.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after acquiring an additional 5,917,423 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $36.00 on Friday. The stock has a market cap of $41.39 billion, a P/E ratio of 27.07, a P/E/G ratio of 3.51 and a beta of 0.86. Teva Pharmaceutical Industries has a twelve month low of $14.99 and a twelve month high of $37.35. The stock has a 50 day moving average of $31.28 and a two-hundred day moving average of $29.81. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The business had revenue of $3.98 billion for the quarter. On average, research analysts forecast that Teva Pharmaceutical Industries will post 2.49 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.